MarketPulse
D

$DBVT

5 articles found
3 positive
0 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

US Eosinophilic Esophagitis Market Poised for Explosive Growth as Novel Drug Classes Emerge

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.
AMGNSNYAZNREGNEPRX+3market growthpharmaceutical pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

DBV Technologies Reports 296M Shares Outstanding as Clinical Pipeline Advances

DBV Technologies reports 296M shares outstanding and 296M voting rights as of March 31, 2026, with updates on VIASKIN® Peanut Patch clinical programs.
DBVTfinancial resultsclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

DBV Technologies Files 2025 Annual Report with 296M Shares Outstanding

DBV Technologies files 2025 annual report disclosing 296M shares outstanding, 295.9M voting rights as VIASKIN Peanut development continues.
DBVTfinancial resultsclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Dbv Technologies

DBV Technologies' Peanut Allergy Patch Shows Strong Phase 3 Data Ahead of FDA Submission

DBV Technologies' peanut allergy patch met Phase 3 goals with 46.6% responder rate versus 14.8% placebo, supporting planned 2026 FDA submission.
DBVTFDA approvalBLA submission
GlobeNewswire Inc.GlobeNewswire Inc.··Dbv Technologies

DBV Technologies' Peanut Allergy Patch Shows Strong Phase 3 Data Ahead of FDA Submission

DBV Technologies announced strong Phase 3 data for VIASKIN® Peanut patch, with 82.8% of treated children showing improved tolerance. FDA submission planned for H1 2026.
DBVTFDA approvalclinical trial results